The diagnosis model of brain stem tumor has been a major breakthrough, and the research results fill the gaps in the field.

(Health Times reporter Dong Wei) the latest study found that 97.3% of patients with cerebrospinal glioma in the cerebrospinal fluid ct DNA can detect tumor information, and cerebrospinal fluid contains more than 50% of tumor mutation information of the proportion reached 91.9%. This means that compared with the traditional way, without piercing, just a cerebrospinal fluid biopsy can confirm brain tumors, and can save medical costs of 30,000 to 80,000. This new model of the world's first brain tumor diagnosis was created by the team of Professor Zhang Wei of Beijing Tiantan Hospital and professor Yan Hai of Duke University School of Medicine. The study, Molecular Pathology Of Gliomas By Brain Stem CT DNA Sequencing, has been published online in the top neurosurgical journal, Neuropathology, with an impact factor of up to 15.872.Professor Zhang Wei, Vice President of Tiantan Hospital in Beijing and Director of Neurosurgery. Professor Zhang Wei is also the President of the Neurosurgeon Branch of the Chinese Physicians Association.
brain stem glioma is an extremely complex and highly heterogeneous group of diseases, the choice of individualized best diagnosis and treatment and the evaluation of efficacy depend on accurate molecular pathology information. However, its pathology detection and efficacy evaluation has always been a difficult problem in the industry, the conventional methods include surgery and stereotactic to the tumor body puncture detection, but the patient has high risk, large nerve function impact, high cost and the defects of material bias, many can not fully reflect the true situation of the tumor body, more can not be carried out many times, real-time.
's team and Professor Bohai's team used the world's only gene panel, which covers almost all of the brain tumor development events (the term gene detection, which refers to genetic detection multiple sites) to sequence the free tumor DNA in the cerebrospinal fluid of brain stem glioma patients in depth. It was found that in 97.3% of patients with cerebrospinal glioma, the mutation information of tumor tissue could be detected in the cerebrospinal fluid ct DNA, in which the cerebrospinal fluid and tumor tissue mutation information were completely consistent with 83%, and the proportion of cerebrospinal fluid containing more than 50% tumor mutation information reached 91.9%.
due to the high detection sensitivity, some patients' cerebrospinal fluid ctDNA can be found in tumor tissue can not detect mutations, showing that cerebrospinal ctDNA can overcome the limitations of single-bit extraction, better reflect tumor heterogeneity. Therefore, only a liquid biopsy of cerebrospinal fluid is required to accurately characterize the tumor properties. Compared with traditional surgery or stereotactic puncture biopsies, this approach not only reduces the risk, but also saves about 30,000 to 80,000 yuan in medical expenses for each patient with a glioma.
it is understood that the research results are currently the world's first original article on the liquid biopsy of cerebrostemoma, filling the gaps in the field of liquid biopsy of cerebral stem glioma, marking China has become a leader in the diagnosis and treatment of glioma symtoma. Since the publication of Neuropathology in 1961, Chinese scholars have published fewer than 30 original theories in the journal as first or communications authors.
Related Reading:
Chinese neurosurgery leader Zhang
Zhang Wei, Vice President of Beijing Tiantan Hospital affiliated with Capital Medical University, Chief Physician of Neurosurgery, Doctoral Mentor. President of the Neurosurgeon Branch of the Chinese Physicians Association. Leading neurosurgery, Executive Director of the World Society of Cranial Surgery. Experts who enjoy special allowances from the State Council.
has been engaged in neurosurgery for 33 years and is committed to the comprehensive diagnosis and treatment of complex tumors at the brain stem and the base of the skull. The international pioneered the improvement and innovation of a variety of cranial brain stem surgery into the road, integrated nerve function protection multi-modal technology, and the first innovative application of brain stem and cranial complex tumor comprehensive diagnosis and treatment, significantly improved the patient's prognosis. As the project sponsor and person in charge, actively advocate and build a multidisciplinary collaborative diagnosis and treatment system, led the formation of the country's first multidisciplinary cooperation platform for the craniofacial base, to carry out multidisciplinary collaborative diagnosis and treatment, significantly improve the status of patients with this disease and prognosis, and lead the formulation of the "Brain stem glioma comprehensive diagnosis and treatment of China Expert Consensus" "hearing neuroma multidisciplinary collaborative diagnosis and treatment of China expertconsensus."
2014, Professor Zhang Wei, in conjunction with Professor Bohai, discovered for the first time in the world that there are specific genetic mutations in gliomas, and the report was published in nature genetics, a world-class academic journal, with an impact factor of more than 30 points. The study is also known as "one of the most important discoveries in the world of neurosurgery in brain stem tumors."
.